RxDoctor Payments Data

Patrick Lowden, MD

Family Medicine · Pittsburgh, PANPI 1770527657

Payments from drug & device makers

$1,008in general payments, 2019–2025

Across 51 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$253
  • Novo Nordisk$167
  • Pfizer$151
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$85
  • Shield Therapeutics Inc$60
  • Lilly USA, LLC$59
  • plus $234 from 9 others

What the payments were for

  • Food & beverage$96396%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,008 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$72,826
Medicare patients
246
Services billed
794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin203$222,395
EliquisApixaban204$188,140
TrulicityDulaglutide50$53,587
OzempicSemaglutide50$49,581
MounjaroTirzepatide46$46,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$43,552
TradjentaLinagliptin53$37,485
XareltoRivaroxaban25$34,317
MyrbetriqMirabegron47$29,134
ProliaDenosumab15$26,260
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$20,051
FarxigaDapagliflozin Propanediol26$18,264
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$15,853
EntrestoSacubitril/Valsartan11$13,134
Atorvastatin Calcium1,259$10,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$18$275,733275 claims
PfizerEliquis$151$188,140204 claims
Lilly USA, LLCTrulicity, Mounjaro$59$100,31496 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$40$73,423115 claims
Novo NordiskOzempic$167$49,58150 claims
AmgenProlia$18$26,26015 claims
AstraZenecaFarxiga$51$18,26426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →